Head-to-head evidence
NNC0662-0419 vs retatrutide
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Obesity
Shared mechanism: GLP-1/GIP/glucagon receptor (triple) · full Obesity pipeline
NNC0662-0419
Developed by Novo Nordisk
NCT06737536 · Phase 1 · completed
Participants were randomly assigned to drug or placebo under double-blind conditions across ascending-dose cohorts, a sound early-safety design, but the primary measure was the number of adverse events rather than a weight or clinical outcome, and results have not yet been reported.
Next expected readout: December 2026 · NCT07184632 (registry estimate)
retatrutide
Developed by Eli Lilly
NCT04881760 · Phase 2 · completed
The trial randomized 338 participants to double-blinded weekly LY3437943 or matched placebo. Its primary clinical endpoint, mean percent change in body weight at Week 24, was significantly favorable for every LY3437943 dose compared with placebo (all p<0.001), supporting a strong evidence grade.
Next expected readout: November 2026 · NCT06662383 (registry estimate)
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: NNC0662-0419's landscape · retatrutide's landscape